Assessing Lebrikizumab in Patients with Moderate to Severe Atopic Dermatitis
Enrolling By Invitation
18 years - 99 years
All
Phase
N/A
1 participants needed
1 Location
Brief description of study
This is an extension study for subjects over the age of 18, diagnosed with moderate-to-severe atopic dermatitis and enrolled in our main study IRB # 845325.
This research study is being conducted to test the safety of lebrikizumab and potential side effects. Procedures include Physical exams, Medical History, blood and urine tests, study medication administered by injection, electronic diary completion and questionnaires.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research,Atopic Dermatitis
-
Age: 18 years - 99 years
-
Gender: All
This is an extension study of our main study IRB # 845325 which is now closed to enrollment. Only subjects who have enrolled in the main study will be enrolled in this study.
Updated on
04 Aug 2024.
Study ID: 851172
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
